Switch theme
Sign up to access all valuation multiples
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.
2006
36
LTM Revenue n/a
LTM EBITDA -$13.5M
$64.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
StemRIM has a last 12-month revenue of n/a and a last 12-month EBITDA of -$13.5M.
In the most recent fiscal year, StemRIM achieved revenue of n/a and an EBITDA of -$13.1M.
StemRIM expects next 12-month revenue of XXX and NTM EBITDA of XXX
See StemRIM valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $15.6M | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | $1.4M | -$13.1M | XXX | XXX | XXX |
| EBITDA Margin | 9% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$12.9M | $1.1M | XXX | XXX | XXX |
| Net Margin | -83% | Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, StemRIM's stock price is JPY 292 (or $2).
StemRIM has current market cap of JPY 18.1B (or $121M), and EV of JPY 9.7B (or $64.7M).
See StemRIM trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $64.7M | $121M | XXX | XXX | XXX | XXX | $-0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, StemRIM has market cap of $121M and EV of $64.7M.
StemRIM's trades at n/a LTM EV/Revenue multiple, and -4.8x LTM EBITDA.
Analysts estimate StemRIM's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for StemRIM and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $64.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpStemRIM's NTM/LTM revenue growth is n/a
StemRIM's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.4M for the same period.
Over next 12 months, StemRIM's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate StemRIM's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for StemRIM and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -1006% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
StemRIM acquired XXX companies to date.
Last acquisition by StemRIM was XXXXXXXX, XXXXX XXXXX XXXXXX . StemRIM acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was StemRIM founded? | StemRIM was founded in 2006. |
| Where is StemRIM headquartered? | StemRIM is headquartered in Japan. |
| How many employees does StemRIM have? | As of today, StemRIM has 36 employees. |
| Is StemRIM publicy listed? | Yes, StemRIM is a public company listed on TKS. |
| What is the stock symbol of StemRIM? | StemRIM trades under 4599 ticker. |
| When did StemRIM go public? | StemRIM went public in 2019. |
| Who are competitors of StemRIM? | Similar companies to StemRIM include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of StemRIM? | StemRIM's current market cap is $121M |
| What is the current EBITDA of StemRIM? | StemRIM's last 12-month EBITDA is -$13.5M. |
| What is the current EV/EBITDA multiple of StemRIM? | Current EBITDA multiple of StemRIM is -4.8x. |
| Is StemRIM profitable? | Yes, StemRIM is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
